Emi Kimoto

11PUBLICATIONS
51CO-AUTHORS
Medical biochemistry - inorganic elements and compoundsPharmacogenomicsPharmaceutical delivery technologiesCheminformatics and quantitative structure-activity relationshipsBehavioural epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 06, 2026
Evaluating the Utility and Constraints of the Competitive Counter Flow (CCF) Assay in OATP1B1 Substrate Profiling.

|Feb 25, 2025
Pyridoxic Acid as Endogenous Biomarker of Renal Organic Anion Transporter Activity: Population Variability and Mechanistic Modeling to Predict Drug-Drug Interactions.

Aarzoo Thakur, Sumathy Mathialagan, Emi Kimoto

|Sep 09, 2024
Utility of Biomarker-Informed Drug Interaction Evaluation in Drug Development and Regulatory Decision Making.

Akihiro Ishiguro, Hiroyuki Kusuhara, Emi Kimoto

|Apr 30, 2024
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.

Charlotte M N Allerton, Joel T Arcari, Lisa M Aschenbrenner

|Dec 16, 2022
Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs.

Jian Lin, Emi Kimoto, Shinji Yamazaki

|Feb 14, 2022
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.

Heather Eng, Alyssa L Dantonio, Eugene P Kadar

Pageof 2

Frequent Collaborators

6 joint publications

Manthena V S Varma

3 joint publications

Heather Eng

2 joint publications

Britton Boras

2 joint publications

Rhys M Jones